Dec 09, 2012 - 12:43 pm
Phase III Study Shows No Overall Benefit for Eribulin over Capecitabine-but TNBC Patients May Have an Advantage
This study compared eribulin to capecitabine in patients with metastatic breast cancer who had already been treated with one or more prior chemotherapy regimens. While overall, the study did not show a benefit for one drug over the other, the subset of triple negative breast cancer patients in the study appeared to do better on the eribulin.
Peter Kauffman, MD, of the Norris Cotton Cancer Center at Dartmouth, said that he thought that the results for TNBC patients were "reasonably encouraging," but noted that there are still many unmet needs for this kind of breast cancer, and that there is a "long way to go."